Houston, TX & St. Louis, MO February 12, 2025 - Integro Theranostics, a clinical-stage company dedicated to advancing surgical outcomes with the use of a unique and proprietary cancer imaging agent, is excited to announce their collaboration with OmniScience, an industry pioneer in AI solutions for clinical trials. By integrating OmniScience’s technology into Integro’s ongoing clinical trials, Integro will bring enhanced image analysis and interpretation, streamlined trial operations, advanced imaging techniques, and surgical outcome predictions to clinical trials.
Integro Theranostics is developing its proprietary fluorescent imaging agent to aid surgeons in the visualization of cancerous tissue, previously undetected in real-time during the surgery. This novel fluorescing molecule specifically binds to and illuminates cancer tissue, facilitating a more complete tumor removal during surgery.
By collaborating with OmniScience, Integro aims to leverage AI to further enhance its mission of improving surgical outcomes initially through the platform of clinical trials. This initiative will initially focus on breast and lung cancers, with plans to expand into other cancer types.
“We are honored to partner with OmniScience to integrate AI into our oncology clinical program,” said Scott Glover, CEO of Integro Theranostics. “This collaboration represents a significant step forward in incorporating AI into the clinical trials process to accelerate and optimize workflows while delivering real-time insights to the clinical team."
OmniScience, known for its award-winning product Vivo, specializes in unifying and analyzing clinical trial data to provide actionable insights that accelerate clinical development. Their expert team of clinical data scientists is dedicated to transforming clinical trials through AI-powered solutions.
“Partnering with Integro Theranostics aligns perfectly with our mission to revolutionize clinical development through AI,” said Angela Holmes, CEO of OmniScience. “We are excited about the potential of this collaboration to improve patient outcomes and democratize access to advanced oncology care.”
Integro Theranostics is a clinical-stage company developing a fluorescent imaging agent, LS301, and associated medical devices with the potential to enable surgeons to readily see and remove cancerous tissue. Integro’s mission is to improve the outcome of cancer surgeries, by providing real-time visual guidance to surgeons in the operating room.
OmniScience is a leader in clinical data science, dedicated to transforming clinical trials through AI-powered solutions. Their award-winning product, Vivo, unifies and analyzes clinical trial data, providing actionable insights that accelerate clinical development. With an expert team of clinical data scientists, OmniScience is committed to advancing human health through innovative technology.
Integro
For more information, please contact:
Nicole Peterson, Administrator, npeterson@kingdomcapital.com
OmniScience
For more information, please contact:
press@omniscience.bio
